UPCC 31216: Phase I/II Trial of Regorafenib Hydroxychloroquine

Enrolling By Invitation

99 years or below

All

Phase 2

44 participants needed

Brief description of study

The main purpose of this study is to find the best dose of hydroxychloroquine (HCQ) when given in combination with regorafenib and entinostat.

You may be eligible for this study if you meet the following criteria:

Updated on 19 Feb 2024. Study ID: 827226

If you need help finding a study or have any questions, please contact us at psom-ocr@pobox.upenn.edu

Message For Enrolling By Invitation Trial

study is selecting its participants from a population, or group of people, decided on by the researchers in advance.